Aptamers Market was valued at USD 2142.8 Million in 2018 and is projected to reach around USD 7456.8 Million by 2025, at a CAGR of 19.50% during the forecast period.
Advancements in aptamer development technologies, increasing R&D investment and the rising number of companies investing in this market are some of the key driving factors responsible for the growth of this market.
Get Sample of This Report@ https://brandessenceresearch.com/requestSample/PostId/145
The chemically synthesized single-standard oligonucleotide (a polynucleotide which contains a relatively small number of nucleotides) are aptamers. Aptamers are developed from more reliable procedures than the manufacture of monoclonal antibodies. These are oligonucleotide which binds to the molecules especially such as protein to be used in numerous applications in field such as research and therapeutics. Numerous advantages offered by these small molecules, in comparison to established antibodies, have also led to higher demand for these molecules across a diverse range of medical applications. They are chemically synthesized, which eliminates batch-to-batch variation and demands less time for development. Due to their extreme versatility they bind to the target that are highly selective and specific including proteins, peptides and carbohydrates. Aptamers are currently being used for the diagnosis of various diseases and detection of the small molecules. Aptamers may be used as pharmaceutical lead section reagents, and functional proteomic levels.
Key Players for Global Aptamers Market Report–
Key Players of Aptamers Market are like Aptamer Sciences, Inc., AMBiotech, Aptagen, LLC., Aptamer Group, Aptus Biotech, Base Pair Biotechnologies, Cambio, NeoVentures Biotechnology Inc., SOMALOGIC INC., TriLink BioTechnologies, LLC, Vivonics Inc., NOXXON Pharma, Ophthotech Corporation, 2bind, NOVAPTECH, Donovan, LLC, ATDBio Ltd., AuramerBio, Barrick Lab, Creative Biogene, AMS Biotechnology (Europe) Limited, IBA GmbH and Kaneka Corporation and others.
Improvement in aptamer development technologies, increasing research and development expenditure and increasing number of companies investing in this market are some of the key driving factors responsible for the growth of this market. Abundant advantages offered by these small molecules, in comparison to established antibodies, have also led to higher demand for these molecules across a wide range of medical applications. However, many aptamers have failed to meet the requisite safety and efficacy standards in clinical studies. Thus, companies have to terminate their clinical investigation during late-stage clinical studies. This factor may hamper the market growth. Moreover, increasing technological advancements in this field can provide new opportunity for the growth of this market.
By Product Type: Nucleic Acid, Peptide, Others,
by Application Type: Diagnostics, Therapeutics, Research & Developments, Others
Aptamers are peptide and oligonucleotide molecules, helps to bind specific target molecule. Aptamers was coined by Andy Ellington. Aptamers are single-stranded DNA or RNA molecules. Due to its selective and specific nature, Aptamers bind to target molecules. Aptamers are used as macromolecular drugs in research and clinical purposes.
Our report studies global Aptamers market and covers historical and forecast data for application, regional and country.
Regional & Country Analysis
North America, U.S., Mexico, Canada , Europe, UK, France, Germany, Italy , Asia Pacific, China, Japan, India, Southeast Asia, South America, Brazil, Argentina, Columbia, The Middle East and Africa, GCC, Africa, Rest of Middle East and Africa
AM Biotechnologies, LLC, Aptagen, LLC, Aptamer Sciences, Inc., Aptamer Solutions Ltd., Aptus Biotech S.L., Base Pair Biotechnologies, Inc. (U.S.), NeoVentures Biotechnology, Inc., NOXXON Pharma, Ophthotech Corporation, SomaLogic, Inc., TriLink BioTechnologies, Inc., Vivonics, Inc., Others
Along with these leading players, there are number of other small and mid-sized players who are coming with huge investment and innovative product launch in the Artificial Organs industry.
Top 5 Companies in the Global Aptamer Market:
Aptagen, LLC is the global leader in aptamer development with more than 25 years of experience in generating high affinity and binding aptamers for small molecules, tissues, proteins and cells. Aptagen was founded in 2004 its operations began after two years in 2006. The company is located in Jacobus, PA., United States. The company creates state-of-the-art target recognition elements for various applications such as diagnostics, therapeutics and bio industrial uses. Aptamers are an emergent technology will become the next evolution in the fields of diagnostics and drug discovery. The company is continually playing a leading role in developing aptamer technology that will help in the treatment of viral infections and diagnosis of various diseases. Aptagen is a leader in the aptamers and built a strong reputation for the positive aptamer results. Aptagen develops aptamers ligands of RNA, DNA, and peptide oligonucleotides. Also, Aptagen offers the industry’s very first Apta-Index at a low-cost service for synthesizing known aptamers for research and development purposes.
AM Biotechnologies (Raptamer Discover Group):
Raptamer Discovery is a group of scientists and engineers having years of experience in developing nucleic acids and aptamers. The company offers unique products and services to its customers and committed to deep research to improve aptamer performance. The company’s scientists have published in respected journals like Nature and Nucleic Acid Research. Raptamer Discovery has worked with leading companies and research institutes in the world. Raptamer Discovery group is part of a private company with annual revenues over the past 5 years is more than USD 300 million. The company has several patents in the aptamer industry, providing products with high quality to be hold leading position in the aptamer and antibody markets across research, diganostic, and therapeutic areas. The company is focused on xaptamer development, a modified aptamer that is better, faster, and cost effective than the normal SELEX-based. X-Aptamer is the next generation evolution of aptamer technology.
Full Research Report @ https://brandessenceresearch.com/biotechnology/global-aptamers-market-2018-2024
About us: Brandessence Market Research and Consulting Pvt. Ltd.
Brandessence market research publishes market research reports & business insights produced by highly qualified and experienced industry analysts. Our research reports are available in a wide range of industry verticals including aviation, food & beverage, healthcare, ICT, Construction, Chemicals, and lot more. Brand Essence Market Research report will be best fit for senior executives, business development managers, marketing managers, consultants, CEOs, CIOs, COOs, and Directors, governments, agencies, organizations, and Ph.D. Students. We have a delivery center in Pune, India and our sales office is in London.
Contact us at: +44-2038074155 or mail us at email@example.com
Interested in this report?